SCHEMBL21611992

SCHEMBL21611992

FC(F)(F)c1cc(SCc2nc(-c3ccc(Cl)cc3)no2)ccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ IDO1 P14902 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ MAPT P10636 5/20 0.47
▸ LMNA P02545 5/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ NOTUM Q6P988 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ TNKS2 Q9H2K2 1/20 0.46
▸ TDP1 Q9NUW8 3/20 0.46
▸ CASP3 P42574 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21611981 0.79 PTGS2 (0.53) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL28838884 0.75 MAPT (0.58) CYP1A2CYP3A4CYP2D6CYP2C9IDO1
SCHEMBL21614743 0.74 DAO (0.38) IDO1MAPTLMNASMN1; SMN2NPC1
SCHEMBL21611942 0.74 PPARD (0.47) CYP2C9CYP2C19MAPTLMNASMN1; SMN2
SCHEMBL14027286 0.72 CYP1A2 (0.54) CYP1A2CYP3A4CYP2D6CYP2C9IDO1
SCHEMBL15495457 0.72 KCNQ1 (0.47) IDO1MAPTNOTUM
SCHEMBL30689317 0.70 HDAC4 (0.41) MAPTLMNANPC1RAB9ATDP1
SCHEMBL15176776 0.70 NOTUM (0.69) CYP1A2CYP3A4CYP2D6CYP2C9IDO1
SCHEMBL22637250 0.70 LOXL2 (0.49) IDO1NOTUM
SCHEMBL5512006 0.69 PPARD (0.55) MAPTLMNASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 CYP1A2 2421/4885CYP3A4 3080/4885CYP2D6 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback